Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Press Micronesia.
Press releases published on July 18, 2025
SAPU Bioscience 重點報導經同業-評審的出版刊物，指出 TGFB2 與年輕胰臟癌患者的存活期息息相關
GlobeNewswire
·
July 18, 2025
數據支持進一步評估試驗性的反義寡核苷酸 OT-101 (trabedersen) 作為胰臟導管腺癌中 TGFB2- 標靶治療方案的效果。 聖地亞哥，加州, July 19, 2025 (GLOBE NEWSWIRE) -- GMP Biotechnology Limited (GMP Bio) 的全資附屬公司 Sapu Biosciences, LLC (Sapu)，與開發針對癌症及罕見疾病的 RNA -標靶和小-分子療法的臨床-階段生物製藥公司 Oncotelic Therapeutics, Inc. ( …
SAPU Bioscience 重点介绍一篇经同行-评审的论文，揭示 TGFB2 与较年轻胰腺癌患者生存期之间的关联
GlobeNewswire
·
July 18, 2025
现有数据支持进一步评估在研反义药物 OT-101（又名 trabedersen）作为靶向 TGFB2 -的治疗策略，用于胰腺导管腺癌的疗效。 圣地亚哥，加利福尼亚州, July 19, 2025 (GLOBE NEWSWIRE) -- Sapu Biosciences, LLC (Sapu)，是 GMP Biotechnology Limited（简称 GMP Bio）的全资子公司，与临床-阶段生物制药公司 Oncotelic Therapeutics, Inc.（OTCQB: OTLC，简称 …
New APOE4 App Uses AI Digital Twins to Help 25% of Population at High Alzheimer's Risk
GlobeNewswire
·
July 18, 2025
Phoenix platform matches users with genetically similar people to predict which interventions actually work. SINGAPORE, July 18, 2025 (GLOBE NEWSWIRE) -- The Phoenix today launched the alpha version of the first app using "digital twin" technology to help …
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
July 18, 2025
SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL …
US Wearable Technology market to grow at a CAGR of 15.4%: Wissen Research
GlobeNewswire
·
July 18, 2025
Sheridan, July 18, 2025 (GLOBE NEWSWIRE) -- According to the latest global wearable market report published by Wissen Research, the US wearable technology market was valued at USD 24 billion in 2024 and is expected to grow at a CAGR of 15.4% during the …
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 18, 2025
NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of …
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
GlobeNewswire
·
July 18, 2025
NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, …
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 18, 2025
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Committee of the …
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
·
July 18, 2025
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock …
Human Appeal USA Mobilizes Relief and Volunteer Event for Texas Flood Victims
GlobeNewswire
·
July 18, 2025
DALLAS, July 18, 2025 (GLOBE NEWSWIRE) -- In the wake of devastating floods across Texas, including persistent overflow from the Guadalupe River, Dallas-based nonprofit Human Appeal USA is taking action to support affected families with both on-the-ground …
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
GlobeNewswire
·
July 18, 2025
WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent …
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
GlobeNewswire
·
July 18, 2025
Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the …
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire
·
July 18, 2025
STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of …
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire
·
July 18, 2025
STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® ( …
Hapbee Reports First-Ever Quarterly Profit in Q2 2025 and Achieves Third Consecutive Quarter of Growth
GlobeNewswire
·
July 18, 2025
VANCOUVER, British Columbia, July 18, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies Inc. (TSXV: HAPB | OTCQB: HAPBF), a wearable wellness technology company and the pioneer of bio-streaming products, today announced its unaudited financial results for the …
Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast
GlobeNewswire
·
July 18, 2025
New York City, NY, July 18, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of muscle building, performance, and strength enhancement, CrazyBulk has emerged as the name reshaping the conversation around legal supplements. As fitness communities move …
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
GlobeNewswire
·
July 18, 2025
EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in late …
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire
·
July 18, 2025
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory …
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
GlobeNewswire
·
July 18, 2025
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene …
Generation Bio Announces 1-for-10 Reverse Stock Split
GlobeNewswire
·
July 18, 2025
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 …